feed,title,long_url,short_url
Benzinga,Gilead's Yescarta Touts Positive Data In Second-Line Large B-Cell Lymphoma Patients,https://benzinga.com/general/biotech/21/06/21744465/gileads-yescarta-touts-positive-data-in-second-line-large-b-cell-lymphoma-patients,https://j.mp/3jlT6oZ
Benzinga,Why Carnival's Stock Is Trading Lower Today,https://benzinga.com/news/21/06/21744419/why-carnivals-stock-is-trading-lower-today,https://j.mp/3jlmKuB
Benzinga,CEL-SCI's Immunotherapy Achieves Survival Benefit Of 14% Exceeding Pre-Defined 10% In Head & Cancer Patients,https://benzinga.com/general/biotech/21/06/21744164/cel-scis-immunotherapy-achieves-survival-benefit-of-14-exceeding-pre-defined-10-in-head-cancer-pa,https://j.mp/3A3q1ES
